CI-1017

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2002
012319982002

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
Four cholinesterase inhibitors have been approved by the US Food and Drug Administration for treating behavioral symptoms of… (More)
Is this relevant?
2002
2002
Previously, we reported on PD 102807 (41) as being the most selective synthetic M(4) muscarinic antagonist identified to date… (More)
Is this relevant?
2000
2000
The M1 muscarinic agonist CI-1017 was administered intravenously to aging rabbits on a daily basis before and during… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2000
2000
The five muscarinic receptor subtypes (M1-M5) are characterized by seven helices that define a transmembrane cavity which serves… (More)
Is this relevant?
2000
2000
The effect of azepino[2,1-b]quinazoline 1,3-dichloro-6,7,8,9,10, 12-hexahydro-, mono-hydrochloride (CI-1002), a tacrine… (More)
Is this relevant?
1998
1998
The synthesis and SAR of a series of (Z)-(+/-)-1-azabicyclo[2.2. 1]heptan-3-one, O-(3-aryl-2-propynyl)oximes are described. The… (More)
Is this relevant?
1998
1998
The 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy focused on new therapeutic approaches for the… (More)
Is this relevant?